Curaleaf Holdings Inc banner
C

Curaleaf Holdings Inc
OTC:CURLF

Watchlist Manager
Curaleaf Holdings Inc
OTC:CURLF
Watchlist
Price: 3.52 USD
Market Cap: $2.6B

EV/GP

4.1
Current
1%
More Expensive
vs 3-y average of 4.1

Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.

EV/GP
4.1
=
Enterprise Value
$5.8B
/
Gross Profit
$1B

Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.

EV/GP
4.1
=
Enterprise Value
$5.8B
/
Gross Profit
$1B

Valuation Scenarios

Curaleaf Holdings Inc is trading above its 3-year average

If EV/GP returns to its 3-Year Average (4.1), the stock would be worth $3.48 (1% downside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-23%
Maximum Upside
+61%
Average Upside
9%
Scenario EV/GP Value Implied Price Upside/Downside
Current Multiple 4.1 $3.52
0%
3-Year Average 4.1 $3.48
-1%
5-Year Average 4.1 $3.55
+1%
Industry Average 3.2 $2.71
-23%
Country Average 6.6 $5.68
+61%

Forward EV/GP
Today’s price vs future gross profit

Not enough data available to calculate forward EV/GP

Peer Comparison

All Multiples
EV/GP
P/E
All Countries
Close
Market Cap EV/GP P/E
CA
Curaleaf Holdings Inc
OTC:CURLF
4.8B USD 4.1 -5.9
US
Eli Lilly and Co
NYSE:LLY
883B USD 17.4 44.1
US
Johnson & Johnson
NYSE:JNJ
553.5B USD 8.8 26.1
CH
Roche Holding AG
SIX:ROG
248.4B CHF 6.3 20.1
UK
AstraZeneca PLC
LSE:AZN
216.3B GBP 6.2 27.4
CH
Novartis AG
SIX:NOVN
221.1B CHF 7.4 20.7
US
Merck & Co Inc
NYSE:MRK
270.2B USD 5.9 15.3
IE
Endo International PLC
LSE:0Y5F
244.4B USD 160.7 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 5.3 12.1
US
Pfizer Inc
NYSE:PFE
151.8B USD 4.2 19.3
US
Bristol-Myers Squibb Co
NYSE:BMY
122B USD 4.3 16.8
P/E Multiple
Earnings Growth PEG
CA
C
Curaleaf Holdings Inc
OTC:CURLF
Average P/E: 22.4
Negative Multiple: -5.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
44.1
32%
1.4
US
Johnson & Johnson
NYSE:JNJ
26.1
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
27.4
25%
1.1
CH
Novartis AG
SIX:NOVN
20.7
14%
1.5
US
Merck & Co Inc
NYSE:MRK
15.3
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
12.1
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.3
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.8
16%
1

Market Distribution

Lower than 87% of companies in Canada
Percentile
13th
Based on 1 947 companies
13th percentile
2.4
Low
0.1 — 3.8
Typical Range
3.8 — 10.6
High
10.6 —
Distribution Statistics
Canada
Min 0.1
30th Percentile 3.8
Median 6.6
70th Percentile 10.6
Max 259 067.6

Curaleaf Holdings Inc
Glance View

Market Cap
2.6B USD
Industry
Pharmaceuticals

Curaleaf Holdings Inc. is a prominent player in the burgeoning cannabis industry. With its roots firmly planted in Massachusetts, Curaleaf quietly grew from a regional entity into a nationwide powerhouse. The company's business model intricately intertwines cultivation, processing, and retail. Curaleaf's vertically integrated structure allows for end-to-end control of its product lifecycle, enhancing both quality assurance and profit margins. They meticulously nurture cannabis plants from seed to harvest, which are then transformed into a range of products, spanning from flower and oil concentrates to edibles and topicals. This comprehensive approach not only supports supply chain efficiency but also significantly bolsters brand consistency and customer satisfaction. Curaleaf's revenue streams flow primarily from its retail operations, where they operate an extensive chain of dispensaries across multiple states. Their strategic acquisitions and mergers have only expanded their footprint, allowing them to tap into diverse markets with varying regulatory landscapes. By establishing a strong retail presence, Curaleaf deftly navigates the complex regulatory frameworks governing cannabis sales, enhancing their market reach and consumer base. Additionally, the company has been proactive in pursuing partnerships and brand extensions, further diversifying its offerings and appealing to a broader audience. This multi-faceted strategy enables Curaleaf to capture a significant share of the growing demand for cannabis-related products, setting a robust foundation for sustained financial growth in an industry poised for expansion.

CURLF Intrinsic Value
Not Available
C
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett